ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 709,95
-0,29%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Jazz Pharmaceuticals PLC (JAZZ)

  7. Jazz Pharmaceuticals PLC (JAZZ) Actualités

JAZZ Jazz Pharmaceuticals PLC

110,01
0,72 (0,66%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Jazz Pharmaceuticals PLC JAZZ NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,72 0,66% 110,01 00:45:55
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
110,14 108,58 111,55 110,01 109,29
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202422:10PRNUSJazz Pharmaceuticals to Participate in the BofA Securities..
01/5/202422:05PRNUSJazz Pharmaceuticals Announces First Quarter 2024 Financial..
24/4/202422:05PRNUSJazz Pharmaceuticals to Present Data Across Growing Oncology..
17/4/202422:15PRNUSJazz Pharmaceuticals to Report 2024 First Quarter Financial..
10/4/202413:45PRNUSJazz Pharmaceuticals to Showcase Expansive Neuroscience..
02/4/202413:30PRNUSJazz Pharmaceuticals Completes Zanidatamab Biologics License..
12/3/202421:15PRNUSJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on..
09/3/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202403:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202403:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202403:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202400:09EDGAR2Form 144 - Report of proposed sale of securities
06/3/202401:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/3/202421:11EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:06EDGAR2Form 8-K - Current report
28/2/202422:05PRNUSJazz Pharmaceuticals Announces Full Year and Fourth Quarter..
27/2/202413:45EDGAR2Form 8-K - Current report
27/2/202413:45PRNUSJazz Pharmaceuticals Appoints Patrick Kennedy to its Board..
21/2/202413:46EDGAR2Form 8-K - Current report
21/2/202413:45PRNUSJazz Pharmaceuticals Appoints Philip Johnson as Chief..
20/2/202422:15PRNUSJazz Pharmaceuticals to Participate in Upcoming March..
14/2/202422:15PRNUSJazz Pharmaceuticals to Report 2023 Full Year and Fourth..
07/2/202408:00PRNUSJazz Pharmaceuticals Enters Definitive Agreement with Redx..
25/1/202423:01EDGAR2Form 8-K - Current report
24/1/202415:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
20/1/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202400:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202400:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202400:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:45EDGAR2Form 8-K - Current report
21/12/202322:05PRNUSJazz Pharmaceuticals Provides Update on Phase 2 Trial of..
20/12/202322:15PRNUSJazz Pharmaceuticals to Present at the 42nd Annual J.P...
15/12/202313:45EDGAR2Form 8-K - Current report
08/12/202319:20PRNUSJazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS..
06/12/202322:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202315:02PRNUSJazz Pharmaceuticals to Present Long-Term and Real-World..
30/11/202313:45PRNUSJazz Pharmaceuticals to Present New Data Highlighting..
14/11/202308:00BWAutifony Announces Exclusive Global License and..
08/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
JAZZ
Jazz Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés